Estimating the budget impact of orphan drugs in Sweden and France 2013–2020
Open Access
- 1 January 2014
- journal article
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 9 (1) , 22
Abstract
The growth in expenditure on orphan medicinal products (OMP) across Europe has been identified as a concern. Estimates of future expenditure in Europe have suggested that OMPs could account for a significant proportion of total pharmaceutical expenditure in some countries, but few of these forecasts have been well validated. This analysis aims to establish a robust forecast of the future budget impact of OMPs on the healthcare systems in Sweden and France.Keywords
This publication has 10 references indexed in Scilit:
- Dutch doctors call for EU evaluation of cost effectiveness of high cost orphan drugs2012
- Market uptake of orphan drugs - a European analysisJournal of Clinical Pharmacy and Therapeutics, 2012
- Estimating the budget impact of orphan medicines in Europe: 2010 - 2020Orphanet Journal of Rare Diseases, 2011
- Pricing and reimbursement of orphan drugs: the need for more transparencyOrphanet Journal of Rare Diseases, 2011
- Orphan drug pricing may warrant a competition law investigationBMJ, 2010
- A comparative study of European rare disease and orphan drug marketsHealth Policy, 2010
- Global Spending on Orphan Drugs in France, Germany, the UK, Italy and Spain during 2007Applied Health Economics and Health Policy, 2010
- Budget impact analysis of orphan drugs in Belgium: estimates from 2008 to 2013Journal of Medical Economics, 2010
- Orphan drug: Development trends and strategiesJournal of Pharmacy and Bioallied Sciences, 2010
- WinBUGS - A Bayesian modelling framework: Concepts, structure, and extensibilityStatistics and Computing, 2000